leadf
logo-loader
viewArcadia Biosciences Inc

Calyxt appoints agribusiness veteran Sarah Reiter as vice president of business development

Reiter most recently served as the chief commercial officer for Arcadia Biosciences

exec
She served as the CEO of Stockton U.S.A. with oversight of the US division of the global multinational bio-ag company from inception to initial sales

Calyxt Inc (NASDAQ:CLXT), a plant-based technology company based in Minnesota, announced Wednesday that it has appointed Sarah Reiter as vice president of business development. 

Reiter will drive new business opportunities at Calyxt to support the company’s recently announced go-to-market strategies.

Reiter is a plant-based technology and agribusiness leader focused on establishing world-class partnerships and value chains that lead to the successful commercialization of emerging technologies for start-up, early-stage and Fortune 500 companies. She will apply her expertise in international business development, acquisitions and product portfolio management in agribusiness to develop, refine and implement the overall commercial strategy for Calyxt's future products, including the prioritization of markets, customers and product types.

READ: Calyxt hits 5 times revenue growth in 2Q results as plant sales expand

“Calyxt continues to build momentum with our go-to-market strategies, and the addition of Sarah to the leadership team will help us to optimize and execute on these strategies going forward,” said CEO Jim Blome in a statement.

“Her proven success in the plant-based innovation sector is an ideal match for our technology, positioning us to be even more responsive to evolving consumer, sustainability and marketplace demands."

With more than 25 years of expertise in agribusiness, Reiter most recently served as the chief commercial officer of Arcadia Biosciences Inc (NASDAQ:RKDA) where she led the company’s commercial and product portfolio strategies and sales to consumer-packaged goods companies globally. 

Prior to Arcadia Biosciences, she served as the CEO of Stockton U.S.A. with oversight of the US division of the global multinational bio-ag company from inception to initial sales. She earned her Master’s Certificate in Business Analysis from the Villanova School of Continuing Education and her Bachelor’s degree from the University of California, Davis.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Arcadia Biosciences Inc

Price: 3.3 USD

NASDAQ:RKDA
Market: NASDAQ
Market Cap: $35.75 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arcadia Biosciences Inc named herein, including the promotion by the Company of Arcadia Biosciences Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Arcadia Biosciences reports strong 2Q revenue despite coronavirus impact

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Matthew Plavan tells Proactive the California-based group's 2Q revenue growth was fueled by GLA sales and GoodWheat royalties. Plavan says the company also cinched a trio of recent GoodWheat agreements: a collaboration with Corner Foods to bring its...

on 08/13/2020

2 min read